Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Belley

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|November 8, 2017
Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic ModelAdam Belley, Francis F Arhin, Greg Moeck
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2003
Identification and characterization of a cyclooxygenase-like enzyme from Entamoeba histolyticaIndranil Dey, Kathy Keller, Adam Belley, et al.
Antimicrobial Agents and Chemotherapy|April 13, 2016
Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing StateAdam Belley, David Lalonde Seguin, Francis Arhin, et al.
Diagnostic Microbiology and Infectious Disease|July 23, 2017
In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococciFrancis F Arhin, David Lalonde Seguin, Adam Belley, et al.
Journal of Global Antimicrobial Resistance|March 22, 2021
Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactamAdam Belley, Ian Morrissey, Stephen Hawser, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2017
Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model of InfectionAdam Belley, David Lalonde-Séguin, Francis F Arhin, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2008
Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant EnterococcusAdam Belley, Robert Harris, Terry Beveridge, et al.
Current Protocols in Microbiology|February 5, 2010
Characterization of the in vitro activity of novel lipoglycopeptide antibioticsFrancis F Arhin, Adam Belley, Geoffrey A McKay, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2021
Sigmoid <i>E</i><sub>max</sub> Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with CefepimePhilipp Knechtle, Stuart Shapiro, Ian Morrissey, et al.
Antimicrobial Agents and Chemotherapy|October 24, 2012
Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infectionAdam Belley, Francis F Arhin, Ingrid Sarmiento, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|November 8, 2017
Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic ModelAdam Belley, Francis F Arhin, Greg Moeck
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2003
Identification and characterization of a cyclooxygenase-like enzyme from Entamoeba histolyticaIndranil Dey, Kathy Keller, Adam Belley, et al.
Antimicrobial Agents and Chemotherapy|April 13, 2016
Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing StateAdam Belley, David Lalonde Seguin, Francis Arhin, et al.
Diagnostic Microbiology and Infectious Disease|July 23, 2017
In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococciFrancis F Arhin, David Lalonde Seguin, Adam Belley, et al.
Journal of Global Antimicrobial Resistance|March 22, 2021
Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactamAdam Belley, Ian Morrissey, Stephen Hawser, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2017
Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model of InfectionAdam Belley, David Lalonde-Séguin, Francis F Arhin, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2008
Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant EnterococcusAdam Belley, Robert Harris, Terry Beveridge, et al.
Current Protocols in Microbiology|February 5, 2010
Characterization of the in vitro activity of novel lipoglycopeptide antibioticsFrancis F Arhin, Adam Belley, Geoffrey A McKay, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2021
Sigmoid <i>E</i><sub>max</sub> Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with CefepimePhilipp Knechtle, Stuart Shapiro, Ian Morrissey, et al.
Antimicrobial Agents and Chemotherapy|October 24, 2012
Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infectionAdam Belley, Francis F Arhin, Ingrid Sarmiento, et al.
Pageof 3